UK markets closed
  • NIKKEI 225

    29,188.17
    +679.62 (+2.38%)
     
  • HANG SENG

    28,755.34
    +133.42 (+0.47%)
     
  • CRUDE OIL

    61.65
    +0.30 (+0.49%)
     
  • GOLD FUTURES

    1,782.10
    -11.00 (-0.61%)
     
  • DOW

    33,813.89
    -323.42 (-0.95%)
     
  • BTC-GBP

    38,263.37
    -2,008.68 (-4.99%)
     
  • CMC Crypto 200

    1,235.17
    -7.89 (-0.63%)
     
  • ^IXIC

    13,817.25
    -132.97 (-0.95%)
     
  • ^FTAS

    3,965.04
    +29.40 (+0.75%)
     

Global Vaccine Partnering Terms and Agreements Directory 2014-2020: Access to Headline, Upfront, Milestone and Royalty Data

Research and Markets
·5-min read

Dublin, March 22, 2021 (GLOBE NEWSWIRE) -- The "Global Vaccine Partnering Terms and Agreements 2014-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

The Global Vaccine Partnering Terms and Agreements 2014-2020: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 800 vaccine deals.

This report contains a comprehensive listing of all vaccine partnering deals announced since January 2014, including financial terms where available, including over 800 links to online deal records of actual vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The report takes readers through the vaccine deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering vaccine partnering deals.

The report presents average financial deal terms values for vaccine deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The middle section of the report explores the leaders in the vaccine partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.

One of the key highlights of the report is that over 800 online deals records of actual vaccine deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference.

Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.

Global Vaccine Partnering Terms and Agreements 2014-2020: Deal trends, players and financials includes:

  • Trends in vaccine dealmaking in the biopharma industry since 2014

  • Analysis of vaccine deal structure

  • Access to headline, upfront, milestone and royalty data

  • Case studies of real-life vaccine deals

  • Access to over 800 vaccine deal documents

  • The leading vaccine deals by value since 2014

  • Most active vaccine dealmakers since 2014

  • The leading vaccine partnering resources

In Global Vaccine Partnering Terms and Agreements 2014-2020: Deal trends, players and financials, the available contracts are listed by:

  • Company A-Z

  • Headline value

  • Stage of development at signing

  • Deal component type

  • Therapy target

  • Specific technology type

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise vaccine rights granted or optioned?

  • What is actually granted by the agreement to the partner company?

  • What exclusivity is granted?

  • What is the payment structure for the deal?

  • How are sales and payments audited?

  • What is the deal term?

  • How are the key terms of the agreement defined?

  • How are IPRs handled and owned?

  • Who is responsible for commercialization?

  • Who is responsible for development, supply, and manufacture?

  • How is confidentiality and publication managed?

  • How are disputes to be resolved?

  • Under what conditions can the deal be terminated?

  • What happens when there is a change of ownership?

  • What sublicensing and subcontracting provisions have been agreed?

  • Which boilerplate clauses does the company insist upon?

  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

  • Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Vaccines dealmaking
2.1. Introduction
2.2. Vaccines partnering over the years
2.3. Most active Vaccines dealmakers
2.4. Vaccines partnering by deal type
2.5. Vaccines partnering by therapy area
2.6. Deal terms for Vaccines partnering
2.6.1 Vaccines partnering headline values
2.6.2 Vaccines deal upfront payments
2.6.3 Vaccines deal milestone payments
2.6.4 Vaccines royalty rates

Chapter 3 - Leading Vaccines deals
3.1. Introduction
3.2. Top Vaccines deals by value

Chapter 4 - Most active Vaccines dealmakers
4.1. Introduction
4.2. Most active Vaccines dealmakers
4.3. Most active Vaccines partnering company profiles

Chapter 5 - Vaccines contracts dealmaking directory
5.1. Introduction
5.2. Vaccines contracts dealmaking directory

Chapter 6 - Vaccines dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Vaccines deals by company A-Z

  • Appendix 2 - Vaccines deals by stage of development

  • Discovery

  • Preclinical

  • Phase I

  • Phase II

  • Phase III

  • Regulatory

  • Marketed

  • Formulation

  • Appendix 3 - Vaccines deals by deal type

  • Asset purchase

  • Assignment

  • Bigpharma outlicensing

  • Co-development

  • Collaborative R&D

  • Co-market

  • Co-promotion

  • CRADA

  • Cross-licensing

  • Development

  • Distribution

  • Equity purchase

  • Evaluation

  • Grant

  • Joint venture

  • Licensing

  • Manufacturing

  • Marketing

  • Material transfer

  • Option

  • Promotion

  • Research

  • Settlement

  • Spin out

  • Sub-license

  • Supply

  • Technology transfer

  • Termination

  • Appendix 4 - Vaccines deals by therapy area

  • Anaesthetics

  • Cardiovascular

  • Central Nervous System

  • Dental

  • Gastrointestinal

  • Hematology

  • Immunology

  • Infectives

  • Metabolic

  • Musculoskeletal

  • Oncology

  • Ophthalmics

  • Orphan disease

  • Pediatrics

  • Psychiatry

  • Respiratory

  • Appendix 5 -Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/r/hziroh

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900